Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Terminated 4Completed 2Recruiting 1Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Plasma cell 1

Conditions

Prostatic Neoplasms 2Recurrence 1Multiple Myeloma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 140Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × OTHER × erdafitinib × Clear all
NCT04754425 2026-02-06

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
11 enrolled
Genitourinary

Prostatic Neoplasms

NCT03999515 2023-09-28

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

University of Washington

Phase 2 Terminated
3 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT03827850 2023-06-09

FIND

Lung Cancer Group Cologne

Phase 2 Terminated
22 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02952573 2020-09-17

Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement

University Health Network, Toronto

Phase 2 Terminated
20 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡